Traded Dec 1, 2025 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Loading…
Traded Nov 5, 2025 · Filed Nov 8, 2025
Corcept Therapeutics's Chief Development Officer sold $23K of Corcept Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$22,884
Shares × reported transaction price
1 day after results of Nov 4, 2025, 111 days before results of Feb 24, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −0.5% | −2.3% | +1.8% |
| 30 days | +13.0% | +0.9% | +12.1% |
| 90 days | −45.3% | +1.8% | −47.1% |
| 180 days | −32.2% | +8.5% | −40.7% |
Past results only. Not a forecast.
Traded Dec 1, 2025 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Dec 1, 2025 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Traded Dec 2, 2025 · filed 2 days later
Gift or transfer — classified separately from trades.